Loading clinical trials...
Loading clinical trials...
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06203457 · Primary Sjögren's Syndrome
NCT06484855 · Primary Sjögren's Syndrome
NCT05817669 · Primary Sjögren's Syndrome
NCT06862284 · Primary Sjögren's Syndrome (pSS)
NCT06432101 · Primary Sjögren's Syndrome
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Mineola, New York
Novartis Investigative Site
Duncansville, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions